Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2005

01-06-2005 | Poster Presentation

Independent prognostic value of somatic TP53gene mutations in 1794 breast cancer patients

Authors: M Olivier, A Langerød, P Carrieri, J Bergh, S Klaar, J Eyfjord, C Theillet, C Rodriguez, R Lidereau, I Bièche, J Varley, Y Bignon, N Uhrhammer, R Winqvist, A Jukkola-Vuorinen, D Niederacher, S Kato, C Ishioka, P Hainaut, A-L Børresen-Dale

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

The prognostic significance of TP53 mutations in breast cancer has been investigated in several studies, but the independency of TP53 towards other prognostic factors and the nature of the mutations that may carry a worse prognosis are still unclear. …
Metadata
Title
Independent prognostic value of somatic TP53gene mutations in 1794 breast cancer patients
Authors
M Olivier
A Langerød
P Carrieri
J Bergh
S Klaar
J Eyfjord
C Theillet
C Rodriguez
R Lidereau
I Bièche
J Varley
Y Bignon
N Uhrhammer
R Winqvist
A Jukkola-Vuorinen
D Niederacher
S Kato
C Ishioka
P Hainaut
A-L Børresen-Dale
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1178

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue

Poster Presentation

RNA integrity number: towards standardization of RNA quality assessment for better reproducibility and reliability of gene expression experiments

Oral Presentation

Targeting estrogen to kill ER-positive and ER-negative breast cancer

Oral Presentation

Genomic profiling of breast cancer

Oral Presentation

ERβ in normal and malignant breast

Poster Presentation

Expression of wild-type and mutated TP53in breast carcinomas

Poster Presentation

Who gets cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits